| Drug General Information |
| Drug ID |
D02NNT
|
| Former ID |
DIB019310
|
| Drug Name |
compound 1d
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C17H15F2N7
|
| InChI |
InChI=1S/C17H15F2N7/c1-9-5-15(26-25-9)23-17-13(19)6-11(7-20)16(24-17)22-10(2)14-4-3-12(18)8-21-14/h3-6,8,10H,1-2H3,(H3,22,23,24,25,26)/t10-/m0/s1
|
| InChIKey |
HIHOEGPXVVKJPP-JTQLQIEISA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
muscle, skeletal, receptor tyrosine kinase |
Target Info |
Inhibitor |
[1]
|
|---|
| Tyrosine-protein kinase JAK2 |
Target Info |
Inhibitor |
[1]
|
| FGF-3 receptor |
Target Info |
Inhibitor |
[1]
|
| Trk receptor |
Target Info |
Inhibitor |
[1]
|
| Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[1]
|
| Proto-oncogene tyrosine-protein kinase receptor ret |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Cholinergic synapse
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infectionhsa04010:MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancer
|
|
Central carbon metabolism in cancerhsa04062:Chemokine signaling pathway
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiencyhsa04144:Endocytosis
|
|
Thyroid cancer
|
|
Central carbon metabolism in cancer
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
CCKR signaling map STP00021:FGF signaling pathwayP00036:Interleukin signaling pathway
|
|
Pathway Interaction Database
|
Endothelins
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
S1P3 pathway
|
|
SHP2 signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
IFN-gamma pathway
|
|
ErbB2/ErbB3 signaling events
|
|
IL3-mediated signaling events
|
|
IL6-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL23-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
Notch-mediated HES/HEY networkil4_2pathway:IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
Signaling events mediated by TCPTP
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5ret_pathway:Signaling events regulated by Ret tyrosine kinase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
Prolactin receptor signaling
|
|
RMTs methylate histone arginines
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
RAF activation
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interleukin receptor SHC signaling
|
|
Growth hormone receptor signaling
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-2033514:FGFR3 mutant receptor activationR-HSA-170984:ARMS-mediated activation
|
|
NGF-independant TRKA activation
|
|
PI3K/AKT activationR-HSA-114604:GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
Interleukin-2 signaling
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Type II interferon signaling (IFNG)
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Interleukin-2 signaling
|
|
Signaling by SCF-KIT
|
|
Prolactin receptor signaling
|
|
Growth hormone receptor signaling
|
|
JAK/STAT
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
IL17 signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
IL-5 Signaling PathwayWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Bladder Cancer
|
|
Neural Crest Differentiation
|
|
Signaling by FGFRWP382:MAPK Signaling Pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
NGF signalling via TRKA from the plasma membraneWP49:IL-2 Signaling Pathway
|
|
Interleukin-7 signaling
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Interleukin-3, 5 and GM-CSF signalingWP706:SIDS Susceptibility Pathways
|
|
Dopaminergic Neurogenesis
|
| References |
| REF 1 | In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. |
|---|
